Vistagen announces issuance of u.s. patent for ph80 nasal spray for treatment of migraine

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (cns) disorders, today announced that the u.s. patent and trademark office (uspto) has granted a u.s. patent for vistagen's ph80 nasal spray for treatment of migraine. the newly issued patent will be in effect until at least 2040.
VTGN Ratings Summary
VTGN Quant Ranking